A New Strategy to Find Targets for Anticancer Therapy : Chemokine CXCL14BRAK Is a Multifunctional Tumor Suppressor for Head and Neck Squamous Cell Carcinoma

Abstract EN

In order to find a suppressor(s) of tumor progression in vivo for head and neck squamous cell carcinoma (HNSCC), we searched for molecules downregulated in HNSCC cells when the cells were treated with epidermal growth factor (EGF), whose receptor is frequently overactivated in HNSCC.

The expression of BRAK, which is also known as CXC chemokine ligand 14 (CXCL14), was downregulated significantly by the treatment of HNSCC cells with EGF as observed by cDNA microarray analysis followed by reverse-transcriptase polymerase chain reaction analysis and western blotting.

The EGF effect on the expression of CXCL14/BRAK was attenuated by the copresence of inhibitors of the EGF receptor, MEK, and ERK.

The rate of tumor formation in vivo of BRAK-expressing vector-transfected tumor cells in athymic nude mice or SCID mice was significantly lower than that of mock vector-transfected ones.

In addition tumors formed in vivo by the BRAK-expressing cells were significantly smaller than those of the mock-transfected ones.

These results indicate that CXCL14/BRAK is a chemokine having suppressive activity toward tumor progression of HNSCC in vivo.

Our approach will be useful to find new target molecules to suppress progression of tumors of various origins in addition to HNSCC.